Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review

 
• By Brenda Sandburg
  
M&A image
Past anticompetitive behaviour of pharma companies could influence FTC merger analysis • Source: Shutterstock

More from Compliance

More from Pink Sheet